Utah has authorized Nolla Health to use an AI system to issue first-time prescriptions and refills for a limited set of topical acne treatments. But the state’s public listing says the pilot’s demonstration period has not started, even as Nolla says Utah adults can enroll through its app; the available information does not establish that pilot prescriptions are being sent to patients.
The distinction matters: the agreement sets conditions for a prescribing pilot, not evidence that it is already operating or that its treatment decisions have been shown to be safe and effective.
What does Utah’s agreement allow Nolla to prescribe?
The state’s pilot listing says the agreement was signed Sept. 22 by Utah’s Office of Artificial Intelligence Policy and Division of Professional Licensing. It covers adults in Utah with mild to moderate acne and a defined list of topical creams and gels. Severe acne, oral medications and isotretinoin are excluded.
The agreement gives limited relief from specified unlicensed-practice and telehealth enforcement for the covered prescribing and participating physicians who rely on the system, provided they follow its terms. It does not grant Nolla a general license to practice medicine or extend to its other products and services.
Utah also cautions that participation in its AI sandbox is not state approval of a product. The Office of Artificial Intelligence Policy said, in a statement reported by SiliconANGLE, “Taking part in our AI sandbox does not mean the State of Utah has approved, endorsed, certified, or vouched for the product”.
When can the AI issue prescriptions without advance review?
The agreement sets out stages for physician oversight. At the start, two Utah-licensed physicians must review every prescription before it is sent. Nolla says this first stage covers its first 100 patients; the state’s summary confirms the review requirement but does not specify that patient count.
Nolla says a later stage would allow the system to send prescriptions before a physician reviews each case. The company describes that stage as covering up to 500 patients, with physicians reviewing cases at least weekly for at least eight weeks. In a subsequent stage, Nolla says physicians would review at least 10% of prescriptions monthly, along with every escalation or side-effect case. The state describes later review as retrospective and then sampling, and requires written approval before the pilot moves between stages.
That sequence makes the degree of oversight a condition of the pilot, not a fixed level of review. The state’s page does not say that Nolla has moved beyond the initial stage—or that the demonstration has begun.
What safeguards and claims should patients weigh?
The agreement requires checks of a patient’s identity and age, limits prescriptions to Utah destinations, and requires pharmacists to be told when a prescription came from AI. It also calls for adverse events to be reported within 24 hours and monthly reports that include how often physicians agree with the system. Nolla must carry professional liability insurance and cannot sell or transfer patient data under the agreement.
Free newsletter
Get the morning briefing
Start each day with the AI stories that matter and why — a short, free email from our newsroom.
Nolla says its app uses an AI assessment and predefined protocols approved by physicians to select topical treatments. The company says people outside the pilot’s eligibility criteria are directed to a clinician or in-person care. Those are descriptions from Nolla, not independent clinical findings.
In its announcement, Nolla also reported that licensed clinicians agreed with its treatment recommendations in 96% of real-world cases. The company did not provide independent validation or underlying study details in that announcement, and the figure is not a result from Utah pilot patients. The state’s listing says the demonstration has not started.
How does this differ from Utah’s earlier AI prescribing pilot?
Utah’s earlier agreement with Doctronic, signed in October 2025, covered renewals of prescriptions that a clinician had already issued. Nolla’s agreement goes further by including first-time prescriptions for specified topical acne treatments. The state says sandbox agreements are narrow and time-limited, participants remain subject to other laws, and the state can end an agreement.
Nolla said Monday, Oct. 5, that Utah residents could download its app and begin enrollment. As of Tuesday, Oct. 6, the state’s listing still said the demonstration period had not started. When the state will mark it as underway, and when the first prescriptions will be sent, remain unresolved.
